Dipartimento Farmaco-Chimico, Universita di Messina, Viale Annunziata, I-98168 Messina, Italy.
J Med Chem. 2010 Mar 25;53(6):2401-8. doi: 10.1021/jm9014026.
Following previous studies we herein report the exploration of the carbonic anhydrase (CA, EC 4.2.1.1) inhibitory effects and enzyme selectivity of a small class of 1-(cyclo)alkylisoquinolines containing a sulfonamide function considered a key feature for inhibiting CA. The results of enzymatic assays against human (h) CA isoforms, hCA I and hCA II (cytosolic, ubiquitous enzymes), hCA IX (transmembrane, tumor-associated), and hCA XIV (transmembrane), suggested that the presence of C-1 small substituents on isoquinoline scaffold controls both inhibitory potency and selectivity. Some derivatives showed potent hCA IX and hCA XIV inhibitory effects at nanomolar concentrations as well as low affinity for the ubiquitous hCA II. Moreover, we report the X-ray crystal structure of one of these derivatives in complex with dominant human isoform II, thus confirming the sulfonamide--zinc interactions. Finally, the results of docking experiments suggested the hypothetic interactions in the catalytic binding site for the most active and selective hCA IX and hCA XIV inhibitor.
基于先前的研究,我们在此报告了一类含磺酰胺基的 1-(环)烷基异喹啉小分子的碳酸酐酶(CA,EC 4.2.1.1)抑制作用和酶选择性的探索,磺酰胺基被认为是抑制 CA 的关键特征。针对人(h)CA 同工型 hCA I 和 hCA II(胞质,普遍存在的酶)、hCA IX(跨膜,与肿瘤相关)和 hCA XIV(跨膜)的酶促测定结果表明,异喹啉骨架上 C-1 位的小取代基既控制抑制效力又控制选择性。一些衍生物在纳摩尔浓度下对 hCA IX 和 hCA XIV 具有很强的抑制作用,对普遍存在的 hCA II 的亲和力较低。此外,我们报告了其中一种衍生物与主要的人同工型 II 的 X 射线晶体结构,从而证实了磺酰胺-锌相互作用。最后,对接实验结果表明,最有效和选择性的 hCA IX 和 hCA XIV 抑制剂在催化结合位点存在假设的相互作用。